News

Important information

BIOJAMP : A Range of Biosimilars for a Seamless Approach

March 1, 2024
JAMP Pharma Group announces the commercial launch and product availability for Pr Jamteki TM, the first biosimilar of Stelara® (ustekinumab) in Canada
February 29, 2024
JAMP Pharma Group Acquires a Pharmaceutical Manufacturing Facility in Lévis, Quebec
January 16, 2024
Discover the one of a kind ready-to-drink gels electrifying the Canadian market!
November 14, 2023
Alvotech and JAMP Pharma announce receipt of marketing authorization for PrJamtekiTM (AVT04), the first biosimilar of Stelara® (ustekinumab)
May 15, 2023
JAMP Pharma Group receives Health Canada approval for Pr JAMP Dapagliflozin, a new generic alternative for the treatment of type 2 diabetes
March 1, 2023
Special offer : 1 bought = 1 free
March 1, 2023
Contest : win a basket full of hair-styling products
January 6, 2023
JAMP Pharma Group receives Health Canada approval for PrJAMP Sitagliptin, a new generic alternative for the treatment of type 2 diabetes
November 15, 2022
The JAMP Pharma Group launches Pr JAMP Apremilast, a new generic alternative for the treatment of plaque psoriasis and psoriatic arthritis
October 11, 2022
New website Wampole.ca